WntResearch

WntResearch

Pressreleases, rapporter och nyheter för WntResearch

Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: Henrik Lawaetz Resigns as CEO of WntResearch
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: Henrik Lawaetz Resigns as CEO of WntResearch
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearchs vd Henrik Lawaetz lämnar sin position
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearchs vd Henrik Lawaetz lämnar sin position
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearchs vd Henrik Lawaetz lämnar sin position
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Reports: WntResearch AB lämnar delårsrapport Q2 April-Juni 2017
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Reports: WntResearch AB lämnar delårsrapport Q2 April-Juni 2017
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Reports: WntResearch AB lämnar delårsrapport Q2 April-Juni 2017
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearch announces that the last patient has been treated in a Phase 1b study with the drug candidate Foxy-5
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearch announces that the last patient has been treated in a Phase 1b study with the drug candidate Foxy-5
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: WntResearch announces that the last patient has been treated in a Phase 1b study with the drug candidate Foxy-5
Spotlight News profile image
Spotlight News
Nyhetsuppdatering från WntResearch
Press release from Companies: Samtliga patienter färdigbehandlade i WntResearchs fas 1b-studie med läkemedelskandidaten Foxy-5
Loading...